SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-229890
Filing Date
2023-09-07
Accepted
2023-09-06 21:22:58
Documents
4
Group Members
ATAI LIFE SCIENCES AG

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d492087dsc13da.htm SC 13D/A 85989
2 EX-99.8 d492087dex998.htm EX-99.8 192736
3 EX-99.9 d492087dex999.htm EX-99.9 31186
4 GRAPHIC g492087dsp33.jpg GRAPHIC 2016
  Complete submission text file 0001193125-23-229890.txt   314552
Mailing Address 6420 ABRAMS SAINT LAURENT A8 H4S 1Y2
Business Address 6420 ABRAMS SAINT LAURENT A8 H4S 1Y2 514-331-7440
IntelGenx Technologies Corp. (Subject) CIK: 0001098880 (see all company filings)

IRS No.: 870638336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-82768 | Film No.: 231240824
SIC: 2834 Pharmaceutical Preparations

Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filed by) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations